Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
BMJ Support Palliat Care. 2022 Sep;12(3):245-252. doi: 10.1136/bmjspcare-2021-002960. Epub 2021 May 11.
This meta-analysis aimed to reach a summarised estimate of distress prevalence screened by Distress Thermometer (DT) among patients with breast cancer and compare different pooled prevalence estimated between different subgroups.
Two independent interviewers conducted a systematic search from PubMed, EMBASE, Ovid and Cochrane Library and checked related reviews and meta-analyses for eligible studies. The studies that identified distress of patients with breast cancer with DT were included. After extracting demographic characteristics and distress prevalence, the pooled analysis and the forest plot were completed by using STATA V.12.0 software. We conducted a subgroup analysis based on demographic and methodological characteristics of the studies. The publication bias was estimated by funnel plot.
Seventeen studies describing 3870 patients with breast cancer were included in this meta-analysis. The distress prevalence of patients with breast cancer varied from 25.3% to 71.7% among these studies. The pooled distress prevalence was 50% (95% CI 49% to 52%) for the overall sample. The pooled distress prevalence rates in DT ≥7, DT ≥5 and DT ≥4 subgroups were 37% (95% CI 35% to 40%), 45% (95% CI 40% to 49%) and 62% (95% CI 60% to 65%), respectively. The distress prevalence had statistically significant differences between subgroups, which were differentiated by the initial time of distress identified, papers' publication time, patients' average age and country. There was no publication bias among the included studies.
The distress prevalence was high among patients with breast cancer. Routine and timely screening of distress for patients with breast cancer is of great significance in oncology management.
本荟萃分析旨在汇总使用痛苦温度计（DT）筛查乳腺癌患者的痛苦患病率，并比较不同亚组之间的汇总患病率。
两名独立的访谈员进行了系统的文献检索，检索范围包括 PubMed、EMBASE、Ovid 和 Cochrane Library，并对相关综述和荟萃分析进行了检查，以寻找符合条件的研究。纳入使用 DT 识别乳腺癌患者痛苦的研究。在提取人口统计学特征和痛苦患病率后，使用 STATA V.12.0 软件完成汇总分析和森林图。我们根据研究的人口统计学和方法学特征进行了亚组分析。使用漏斗图估计发表偏倚。
本荟萃分析纳入了 17 项研究，共 3870 例乳腺癌患者。这些研究中，乳腺癌患者的痛苦患病率从 25.3%到 71.7%不等。整体样本的汇总痛苦患病率为 50%（95%CI 49%至 52%）。DT≥7、DT≥5 和 DT≥4 亚组的汇总痛苦患病率分别为 37%（95%CI 35%至 40%）、45%（95%CI 40%至 49%）和 62%（95%CI 60%至 65%）。根据识别痛苦的初始时间、论文发表时间、患者平均年龄和国家的不同，亚组之间的痛苦患病率存在统计学差异。纳入的研究中不存在发表偏倚。
乳腺癌患者的痛苦患病率较高。对乳腺癌患者进行常规和及时的痛苦筛查，对肿瘤学管理具有重要意义。
